Mckesson Corp

McKesson operates as a pharmaceutical and medical supply distributor, connecting manufacturers with healthcare providers including hospitals, retail pharmacies, and clinics. The company generates revenue through distribution fees, purchasing economies of scale, and supply chain management services. McKesson also provides healthcare technology solutions, specialty pharmaceuticals distribution, and oncology practice management services. Its business model relies on high volume, efficient logistics, and maintaining relationships with both drug manufacturers and healthcare facilities across North America.

McKesson benefits from its position as one of the largest pharmaceutical distributors, with essential infrastructure serving healthcare supply chains. The company generates steady cash flows from distribution operations and has diversified into higher-margin specialty pharmaceutical services. Risks include thin margins on commodity distribution, regulatory changes affecting drug pricing, and potential disruption from manufacturers selling directly to providers. The stock typically offers moderate growth with dividend income.

McKesson competes directly with AmerisourceBergen and Cardinal Health, forming the "Big Three" pharmaceutical distributors in the United States. These three companies control the vast majority of pharmaceutical distribution. McKesson also faces competition from Walgreens Boots Alliance in certain specialty distribution segments and regional distributors serving specific geographic markets or therapeutic areas.

McKesson maintains a quarterly dividend yielding approximately 0.34%, demonstrating commitment to returning capital to shareholders while investing in growth. The company has steadily increased its dividend over time, reflecting stable cash flows from its distribution operations. McKesson balances dividend payments with share repurchases and strategic acquisitions, providing investors with income while maintaining financial flexibility to capitalize on market opportunities.

MCK last closed at $879.75, down 0.25% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $637.00 and a high of $999.00. The current price represents 67% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 22 analysts covering MCK, the consensus rating is Strong Buy — 19 rate it a buy, 3 hold, and 0 sell. The average price target sits at $307.39, implying 65% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Mckesson Corp generated $344.98B in revenue during fiscal year 2026, with $3.17B reaching the bottom line as net income. The net profit margin of 0.9% reflects the competitive nature of its industry.

MCK trades at a P/E ratio of 25.12 on trailing earnings of $34.77 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +6.22% (3M), +15.48% (6M), +32.69% (1Y), +6.84% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether MCK is outperforming or lagging the broader market.